Treatment with gefitinib, a selective EGFR RTK, resulted in decreased cell proliferation and decreased microvascular density and VEGF levels in murine renal cell carcinoma [42]. This evidence concerns the gene EGFR and hereditary clear cell renal cell carcinoma.